The Broad Institute has succeeded in getting the first patent for the hot new genome-editing technique.
Financial Growing Pains of a Biotech Illustrations by Tomasz Walenta Large risks and high costs dominate the financial life cycle of a biotechnology company, but the potential payoffs are huge. By Sam Hall and Alastair J.J. Wood Illustrations by Tomasz Walenta Related Articles 2, legacy pharmaceutical companies typically pay biotech licensors a midpoint value of ~$220 million for Phase III drugs, compared with only ~$65 million for drugs in Phase I clinical
August 1, 2008|
September 9, 2008